These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33257454)

  • 21. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.
    Petraitis V; Petraitiene R; Kavaliauskas P; Naing E; Garcia A; Georgiades BN; Echols R; Bonomo RA; Yamano Y; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0061822. PubMed ID: 36154614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
    Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
    Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
    Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
    J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.
    Saisho Y; Katsube T; White S; Fukase H; Shimada J
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 28. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
    Kuai J; Wang X; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections.
    Drwiega EN; Griffith NC; Danziger LH
    Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.
    Weaver K; Stallworth K; Blakely KK
    Nurs Womens Health; 2020 Oct; 24(5):377-382. PubMed ID: 32890463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
    Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
    J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Xiao AJ; Huntington JA; Long J; Caro L
    Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Shortridge D; Streit JM; Mendes R; Castanheira M
    Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
    Katsube T; Nicolau DP; Rodvold KA; Wunderink RG; Echols R; Matsunaga Y; Menon A; Portsmouth S; Wajima T
    J Antimicrob Chemother; 2021 Oct; 76(11):2902-2905. PubMed ID: 34383901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
    Das S; Li J; Riccobene T; Carrothers TJ; Newell P; Melnick D; Critchley IA; Stone GG; Nichols WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible
    Burnard D; Robertson G; Henderson A; Falconer C; Bauer MJ; Cottrell K; Gassiep I; Norton R; Paterson DL; Harris PNA
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review.
    Babidhan R; Lewis A; Atkins C; Jozefczyk NJ; Nemecek BD; Montepara CA; Gionfriddo MR; Zimmerman DE; Covvey JR; Guarascio AJ
    Pharmacotherapy; 2022 Jul; 42(7):549-566. PubMed ID: 35611627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
    Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.